FibroBiologics Inc. FBLG
1.39
0.03
2.21%
as of 25 Sep
- Market cap
- $9.1M
- P/E
- 0.0×
Follow FBLG
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
0.78 | 3.61 | 1.59 | 2.64 |
Net Debt/EBITDA |
0.06 | 2.08 | 0.31 | 0.91 | |
Debt/Assets |
52.30% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
36.58 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.69 | 0.98 | 0.87 | 0.80 | |
Capex/Depreciation |
(0.03) | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(1.85) | (1.42) | (1.16) | (0.52) | |
Cash per Share |
2.26 | 2.19 | 0.39 | 0.56 | |
Shareholders Equity per Share |
0.06 | 2.76 | 0.69 | 0.74 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.06 | 2.76 | 0.69 | 0.74 | |
Free Cash Flow |
(3.98) | (3.16) | (4.36) | (3.29) | |
Working Capital |
(1.48) | 4.59 | 1.08 | 3.64 | |
Capital Expenditures |
(0.01) | 0.00 | — | — | |
Net Current Asset Value |
(3.38) | 2.89 | (0.43) | 2.56 | |
| Other line items | |||||
Quick Ratio |
0.72 | 2.78 | 0.81 | 1.59 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.84) | (1.42) | (1.16) | (0.52) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
1.12 | 1.82 | 1.13 | 1.81 | |
Average Assets |
9.61 | 13.03 | 8.68 | 10.92 | |
Average Common Equity |
1.43 | 4.45 | 2.48 | 2.75 | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates